Digital ‘lens’ on the UK PSF: supporting the digital capabilities of teaching staff in UK HE

This resource can also be used by professional staff who are seeking accreditation via the UK PSF for relevant aspects of their role, e.g. staff who support the use of technologies for learning and/or support the development of digital literacies.

Interdisciplinary experience in the Teacher Training College of Vitoria-Gasteiz: teaching profession module

[EN] The higher education regulation process in Europe, known as the Bologna Process, has involved many changes, mainly in relation to methodology and assessment. The paper given below relates to implementing the new EU study plans into the Teacher Training College of Vitoria-Gasteiz; it is the first interdisciplinary paper written involving teaching staff and related to the Teaching Profession module, the first contained in the structure of the new plans. The coordination of teaching staff is one of the main lines of work in the Bologna Process, which is also essential to develop the right skills and maximise the role of students as an active learning component. The use of active, interdisciplinary methodologies has opened up a new dimension in universities, requiring the elimination of the once componential, individual structure, making us look for new areas of exchange that make it possible for students' training to be developed jointly.

Adapting integrated agriculture aquaculture for HIV and AIDS-affected households: the case of Malawi

The WorldFish Center in conjunction with World Vision Malawi carried out a project to improve income and nutrition status of households affected by HIV and AIDS with funding from the World Bank. The project was implemented in Southern Malawi particularly in the West of Zomba District from July 2005 to June 2006. Through participatory approaches, the project identified constraints that limit HIV and AIDS affected households’ realisation of the benefits from fish farming and adapted technologies and practices for the affected beneficiaries to boost fish production and utilization. Specifically, the project sought (1) to identify the constraints that limit HIV and AIDS affected households to realise the benefits from fish farming and based on the constraints, (2) to adapt technologies and practices for use by the affected beneficiaries to boost fish production and utilization. (PDF cotains 17 pages)

Using the system dynamics paradigm in teaching and learning technological university subjets

2nd International Conference on Education and New Learning Technologies

Indication of pollution in a teaching and research farm reservoir

The production and productivity of a water body is largely dependent on its quality. One major source of water pollution is from the agrochemicals from nearby farmlands. The quality of water in the Obafemi Awolowo University Teaching and Research Farm Reservoir (Ile-Ife, Nigeria) was monitored between October, 1993 and March, 1994. Structured questionnaires were administered to obtain information on the types of agrochemicals in use on the farm. Water samples were collected fortnightly for analyses of the physico-chemical parameters and ionic content of the water. Investigation revealed that 21 agrochemicals had been in use on the farm. The physico-chemical parameters of the water showed that the water was very poor in nutrient. The high concentration of ammonium ion contents of the water shows an indication that the residues of certain agrochemicals got into the water to pollute it. Agrochemicals should be used with great caution on farmlands especially in areas close to water bodies from which man obtains fish and other proteinous foods. This paper also suggests a regular monitoring of water quality of reservoirs in order to pick the earliest signs of pollution

Statistical and econometric analysis of the treatment of HIV/AIDS

The epidemic of HIV/AIDS in the United States is constantly changing and evolving, starting from patient zero to now an estimated 650,000 to 900,000 Americans infected. The nature and course of HIV changed dramatically with the introduction of antiretrovirals. This discourse examines many different facets of HIV from the beginning where there wasn't any treatment for HIV until the present era of highly active antiretroviral therapy (HAART). By utilizing statistical analysis of clinical data, this paper examines where we were, where we are and projections as to where treatment of HIV/AIDS is headed.

Chapter Two describes the datasets that were used for the analyses. The primary database utilized was collected by myself from an outpatient HIV clinic. The data included dates from 1984 until the present. The second database was from the Multicenter AIDS Cohort Study (MACS) public dataset. The data from the MACS cover the time between 1984 and October 1992. Comparisons are made between both datasets.

Chapter Three discusses where we were. Before the first anti-HIV drugs (called antiretrovirals) were approved, there was no treatment to slow the progression of HIV. The first generation of antiretrovirals, reverse transcriptase inhibitors such as AZT (zidovudine), DDI (didanosine), DDC (zalcitabine), and D4T (stavudine) provided the first treatment for HIV. The first clinical trials showed that these antiretrovirals had a significant impact on increasing patient survival. The trials also showed that patients on these drugs had increased CD4+ T cell counts. Chapter Three examines the distributions of CD4 T cell counts. The results show that the estimated distributions of CD4 T cell counts are distinctly non-Gaussian. Thus distributional assumptions regarding CD4 T cell counts must be taken, into account when performing analyses with this marker. The results also show the estimated CD4 T cell distributions for each disease stage: asymptomatic, symptomatic and AIDS are non-Gaussian. Interestingly, the distribution of CD4 T cell counts for the asymptomatic period is significantly below that of the CD4 T cell distribution for the uninfected population suggesting that even in patients with no outward symptoms of HIV infection, there exists high levels of immunosuppression.

Chapter Four discusses where we are at present. HIV quickly grew resistant to reverse transcriptase inhibitors which were given sequentially as mono or dual therapy. As resistance grew, the positive effects of the reverse transcriptase inhibitors on CD4 T cell counts and survival dissipated. As the old era faded a new era characterized by a new class of drugs and new technology changed the way that we treat HIV-infected patients. Viral load assays were able to quantify the levels of HIV RNA in the blood. By quantifying the viral load, one now had a faster, more direct way to test antiretroviral regimen efficacy. Protease inhibitors, which attacked a different region of HIV than reverse transcriptase inhibitors, when used in combination with other antiretroviral agents were found to dramatically and significantly reduce the HIV RNA levels in the blood. Patients also experienced significant increases in CD4 T cell counts. For the first time in the epidemic, there was hope. It was hypothesized that with HAART, viral levels could be kept so low that the immune system as measured by CD4 T cell counts would be able to recover. If these viral levels could be kept low enough, it would be possible for the immune system to eradicate the virus. The hypothesis of immune reconstitution, that is bringing CD4 T cell counts up to levels seen in uninfected patients, is tested in Chapter Four. It was found that for these patients, there was not enough of a CD4 T cell increase to be consistent with the hypothesis of immune reconstitution.

In Chapter Five, the effectiveness of long-term HAART is analyzed. Survival analysis was conducted on 213 patients on long-term HAART. The primary endpoint was presence of an AIDS defining illness. A high level of clinical failure, or progression to an endpoint, was found.

Chapter Six yields insights into where we are going. New technology such as viral genotypic testing, that looks at the genetic structure of HIV and determines where mutations have occurred, has shown that HIV is capable of producing resistance mutations that confer multiple drug resistance. This section looks at resistance issues and speculates, ceterus parabis, where the state of HIV is going. This section first addresses viral genotype and the correlates of viral load and disease progression. A second analysis looks at patients who have failed their primary attempts at HAART and subsequent salvage therapy. It was found that salvage regimens, efforts to control viral replication through the administration of different combinations of antiretrovirals, were not effective in 90 percent of the population in controlling viral replication. Thus, primary attempts at therapy offer the best change of viral suppression and delay of disease progression. Documentation of transmission of drug-resistant virus suggests that the public health crisis of HIV is far from over. Drug resistant HIV can sustain the epidemic and hamper our efforts to treat HIV infection. The data presented suggest that the decrease in the morbidity and mortality due to HIV/AIDS is transient. Deaths due to HIV will increase and public health officials must prepare for this eventuality unless new treatments become available. These results also underscore the importance of the vaccine effort.

The final chapter looks at the economic issues related to HIV. The direct and indirect costs of treating HIV/AIDS are very high. For the first time in the epidemic, there exists treatment that can actually slow disease progression. The direct costs for HAART are estimated. It is estimated that the direct lifetime costs for treating each HIV infected patient with HAART is between $353,000 to $598,000 depending on how long HAART prolongs life. If one looks at the incremental cost per year of life saved it is only $101,000. This is comparable with the incremental costs per year of life saved from coronary artery bypass surgery.

Policy makers need to be aware that although HAART can delay disease progression, it is not a cure and HIV is not over. The results presented here suggest that the decreases in the morbidity and mortality due to HIV are transient. Policymakers need to be prepared for the eventual increase in AIDS incidence and mortality. Costs associated with HIV/AIDS are also projected to increase. The cost savings seen recently have been from the dramatic decreases in the incidence of AIDS defining opportunistic infections. As patients who have been on HAART the longest start to progress to AIDS, policymakers and insurance companies will find that the cost of treating HIV/AIDS will increase.

Análise de sobrevida dos pacientes com AIDS atendidos em um centro de pesquisa no Rio de Janeiro : 1986 a 2000

O objetivo deste trabalho é determinar o tempo decorrido e fatores relacionados a sobrevida, a partir do diagnóstico da AIDS dos pacientes atendidos no Centro de Pesquisa Hospital Evandro Chagas (CPqHEC). Comparar a sobrevida segundo os critérios definição de caso de AIDS estabelecidos pelo Centro de controle de doenças e prevenção dos EUA (CDC) em 1987 e 1993 e pelo Ministério da Saúde Brasil em 1998. De um total de 1591 indivíduos com sorologia positiva para HIV, cadastrados entre 1986 a 1999, foi selecionada uma amostra aleatória sistemática com 392 indivíduos, sendo identificados 193 casos de AIDS pelo critério CDC 1993. A sobrevida foi considerada como o tempo decorrido da data do diagnóstico da AIDS ao óbito (falha), sendo a censura definida para os pacientes com perda de seguimento ou que permaneceram vivos até dezembro de 2000, com a data da censura igual a data do último atendimento. A duração da sobrevida foi descrita através do método de Kaplan-Meier, sendo comparadas as funções de sobrevida das categorias das variáveis pelo teste log-rank. Um modelo com os co-fatores de maior relevância na sobrevida foi ajustado, utilizando-se o modelo dos riscos proporcionais de Cox. Dos 193 pacientes com AIDS, 92 (47,7%) morreram, 21 (10,9%) abandonaram o tratamento, e 80 (41,7%) permaneceram vivos até o fim do estudo. Encontramos sobrevida relativamente alta nos três critérios de definição de caso avaliados, em parte explicada pelos casos serem procedentes de um único hospital de pesquisa, com alto grau de conhecimento na condução da doença. A profilaxia primária para PPC foi preditor de melhor sobrevida. Casos com AIDS definida por herpes zoster apresentaram melhor prognóstico e os definidos por duas doenças o pior prognóstico.

Vivendo com HIV/AIDS : cuidado, tratamento e adesão na experiência do grupo com vida

A presente dissertação aborda a adesão ao tratamento. Entendendo que tratamento não se restringe a prescrição e tomada de medicamentos, o Ambulatório de Medicina Integral do Hospital Universitário Pedro Ernesto (AMI/HUPE/UERJ) desenvolve um trabalho multidisciplinar com pacientes soropositivos. Durante o acompanhamento destes pacientes constatou-se a importância da criação de um espaço coletivo que permitisse a reflexão sobre o viver e conviver com HIV/AIDS. O Grupo COM VIDA começou as suas atividades em julho de 1996, contando com uma equipe multidisciplinar formada por médico, psicólogo e profissional do Serviço Social. Com a evolução do trabalho, a equipe foi lidando a cada dia mais e mais com as questões suscitadas pela terapia anti-retroviral. A adesão ao tratamento passou a ser um pilar no manejo do tratamento de pacientes com HIV/AIDS. A abordagem biopsicossocial do paciente constitui-se como facilitadora da adesão ao processo terapêutico. As variáveis que envolvem a intervenção terapêutica mencionada são consoantes ao processo de adoecimento humano que é complexo e dinâmico, na medida que pressupõe a capacidade de reagir para a pessoa que adoece tem um sentido e um significado. E tornando-se sujeito no processo de adoecimento e cuidado que o paciente desenvolve capacidade autônoma, o que contribui para alcançar os objetivos terapêuticos pactuados.

A constituição de 1988, as políticas públicas de saúde e o fornecimento de medicamentos para as pessoas portadoras de HIV/AIDS

A discussão sobre a atuação do Estado nas políticas públicas de Saúde remonta a constituição alemã de Weimar, em 1919 até os dias de hoje. No Brasil, esta discussão avança em dois momentos da década de 80: o primeiro é o registro dos casos de AIDS inicialmente detectados em 1980, enfermidade vista como problema de determinados grupos sociais de comportamentos desviantes e não da sociedade como um todo, acarretando movimento por parte da sociedade civil atingida pela doença, através de organizações não-governamentais que se especializaram na luta contra a discriminação do portador do vírus HIV e do doente de AIDS. O segundo momento é a promulgação da Constituição da República de 1988, texto normativo que estabeleceu diretrizes referentes ao fornecimento de serviços de saúde por parte do Estado, elevando a saúde a categoria de direito fundamental social. Estes movimentos liderados pelas organizações não-governamentais, pressionaram o Estado, através do Poder Judiciário para garantir o cumprimento de seus direitos de cidadãos previstos na Constituição, uma vez que o desrespeito aos direitos das pessoas que vivem com HIV/AIDS era crescente no Brasil. Para desenvolvimento da presente tese foi utilizada a pesquisa documental das decisões em todas as instâncias do Poder Judiciário, passando pelo Tribunal Estadual do Rio de Janeiro até chegar a cúpula do Poder Judiciário, o Supremo Tribunal Federal, aprofundando o estudo nas decisões que deferiram os pedidos referentes ao fornecimento de medicamentos para os doentes de AIDS. Foram utilizados documentos doutrinários para fundamentar a necessidade da aplicabilidade das normas constitucionais de forma imediata e não como meros programas para o poder público. Ao levantar estes documentos, observou-se que a previsão constitucional, e as decisões dos órgãos do Poder Judiciário, caminhavam não só para garantir os direitos das pessoas que vivem com HIV/AIDS, mas também para estender esta política pública a outras doenças degenerativas do organismo humano de forma a possibilitar a aplicação da previsão normativa não somente àquela doença.